OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
BörsenkürzelOPK
Name des UnternehmensOPKO Health Inc
IPO-datumNov 02, 1995
CEOCruz (Tony F)
Anzahl der mitarbeiter2997
WertpapierartOrdinary Share
GeschäftsjahresendeNov 02
Addresse- -
Stadt- -
BörseNASDAQ OMX - NASDAQ BASIC
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelOPK
IPO-datumNov 02, 1995
CEOCruz (Tony F)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten